A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults



French, Neil ORCID: 0000-0003-4814-8293, Gordon, Stephen B ORCID: 0000-0001-6576-1116, Mwalukomo, Thandie, White, Sarah A, Mwafulirwa, Gershom, Longwe, Herbert, Mwaiponya, Martin, Zijlstra, Eduard E, Molyneux, Malcolm E and Gilks, Charles F
(2010) A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. MALAWI MEDICAL JOURNAL, 28 (3). pp. 115-122.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Background</h4><i>Streptococcus pneumoniae</i> is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed.<h4>Methods</h4>In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. The primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or serotype 6A.<h4>Results</h4>From February 2003 through October 2007, we followed 496 patients (of whom 44% were male and 88% were HIV-seropositive) for 798 person-years of observation. There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infected subgroup. In 24 patients, there were 19 episodes that were caused by vaccine serotypes and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 occurred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after vaccination was significantly lower in the vaccine group than in the placebo group (3 vs. 17, P = 0.002), and the number of minor adverse events was significantly higher in the vaccine group (41 vs. 13, P = 0.003).<h4>Conclusions</h4>The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current Controlled Trials number, ISRCTN54494731.).

Item Type: Article
Uncontrolled Keywords: Pediatric, Immunization, Lung, Prevention, Vaccine Related, Clinical Trials and Supportive Activities, Clinical Research, Pneumonia & Influenza, Infectious Diseases, HIV/AIDS, Pneumonia, 6 Evaluation of treatments and therapeutic interventions, 3 Prevention of disease and conditions, and promotion of well-being, 6.1 Pharmaceuticals, 3.4 Vaccines, Infection, 3 Good Health and Well Being, AIDS-Related Opportunistic Infections, Adolescent, Adult, Aged, CD4 Lymphocyte Count, Double-Blind Method, Female, HIV Infections, Heptavalent Pneumococcal Conjugate Vaccine, Humans, Intention to Treat Analysis, Male, Middle Aged, Multivariate Analysis, Pneumococcal Vaccines, Pneumonia, Pneumococcal, Risk Factors, Streptococcus pneumoniae, Vaccines, Conjugate, Young Adult
Depositing User: Symplectic Admin
Date Deposited: 02 Dec 2016 16:15
Last Modified: 15 Mar 2024 01:38
DOI: 10.1056/NEJMoa0903029
Open Access URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC51170...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3004743